Keyang Xu

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. doi request reprint Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum
    Keyang Xu
    Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 5:1057-71. 2013
  2. doi request reprint Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry
    Keyang Xu
    Genentech, South San Francisco, CA 94080, USA
    Anal Biochem 412:56-66. 2011
  3. ncbi request reprint Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
    Siddharth Sukumaran
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, California, 94080, USA
    AAPS J . 2016
  4. doi request reprint Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
    Siddharth Sukumaran
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, California, 94080, USA
    Pharm Res 32:1884-93. 2015
  5. pmc Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates
    Donglu Zhang
    Drug Metabolism and Pharmacokinetics D Z, Y M, C E C A H, S C K, Translational Oncology S Y, G D R, BioAnalytical Sciences K X, L L, J H, Discovery Chemistry P S D, T H P, Z P, Protein Chemistry J D S, H K E, Genentech, South San Francisco, California
    Drug Metab Dispos 44:1517-23. 2016
  6. doi request reprint Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
    Ben Quan Shen
    Genentech Inc, 1 DNA Way, S San Francisco, California, USA
    Nat Biotechnol 30:184-9. 2012
  7. ncbi request reprint Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates
    Dian Su
    Genentech, Inc 1 DNA Way, South San Francisco, California 94080, United States
    Anal Chem 88:11340-11346. 2016
  8. doi request reprint Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates
    Ola M Saad
    Department of Bioanalytical Sciences, Assay Development and Technology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 7:1583-604. 2015
  9. doi request reprint Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
    Surinder Kaur
    Genentech, 1 DNA Way, South San Francisco, CA 94080 4990, USA
    Bioanalysis 5:201-26. 2013
  10. doi request reprint Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates
    Leanna R Staben
    Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Chem 8:1112-1119. 2016

Collaborators

Detail Information

Publications15

  1. doi request reprint Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum
    Keyang Xu
    Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 5:1057-71. 2013
    ..The objective of this manuscript was to propose and assess the assays that allow for the characterization of the drug deconjugation in plasma/serum...
  2. doi request reprint Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry
    Keyang Xu
    Genentech, South San Francisco, CA 94080, USA
    Anal Biochem 412:56-66. 2011
    ..Other potential applications of the method may include characterization of posttranslational modifications, protein adducts, and immunogenicity...
  3. ncbi request reprint Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
    Siddharth Sukumaran
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, California, 94080, USA
    AAPS J . 2016
    ....
  4. doi request reprint Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
    Siddharth Sukumaran
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, California, 94080, USA
    Pharm Res 32:1884-93. 2015
    ..General applicability of the model structure was evaluated with two different TDCs...
  5. pmc Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates
    Donglu Zhang
    Drug Metabolism and Pharmacokinetics D Z, Y M, C E C A H, S C K, Translational Oncology S Y, G D R, BioAnalytical Sciences K X, L L, J H, Discovery Chemistry P S D, T H P, Z P, Protein Chemistry J D S, H K E, Genentech, South San Francisco, California
    Drug Metab Dispos 44:1517-23. 2016
    ....
  6. doi request reprint Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
    Ben Quan Shen
    Genentech Inc, 1 DNA Way, S San Francisco, California, USA
    Nat Biotechnol 30:184-9. 2012
    ..Thus, the chemical and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface...
  7. ncbi request reprint Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates
    Dian Su
    Genentech, Inc 1 DNA Way, South San Francisco, California 94080, United States
    Anal Chem 88:11340-11346. 2016
    ....
  8. doi request reprint Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates
    Ola M Saad
    Department of Bioanalytical Sciences, Assay Development and Technology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 7:1583-604. 2015
    ..This review covers both large and small molecule approaches, and uses examples from Kadcyla® (T-DM1) and a THIOMAB™ antibody-drug conjugate to illustrate the process...
  9. doi request reprint Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
    Surinder Kaur
    Genentech, 1 DNA Way, South San Francisco, CA 94080 4990, USA
    Bioanalysis 5:201-26. 2013
    ..Our strategy has involved novel protein structural characterization tools to help understand ADC biotransformations in vivo and use of the analyte knowledge gained to guide the development of quantitative bioanalytical assays...
  10. doi request reprint Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates
    Leanna R Staben
    Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Chem 8:1112-1119. 2016
    ....
  11. ncbi request reprint 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies)
    An Song
    Genentech, South San Francisco, CA, USA
    Bioanalysis 8:2457-2474. 2016
    ..Parts 1 (small molecule bioanalysis using LCMS) and Part 3 (large molecule bioanalysis using LBA, biomarkers and immunogenicity) have been published in the Bioanalysis journal, issues 22 and 23, respectively...
  12. ncbi request reprint Validation of a biotherapeutic immunoaffinity-LC-MS/MS assay in monkey serum: 'plug-and-play' across seven molecules
    Surinder Kaur
    Genentech, Inc, South San Francisco, California, USA
    Bioanalysis 8:1565-1577. 2016
    ..Using similar method conditions, six additional biotherapeutic assays were readily validated in different nonhuman mammalian species, including mouse, rat and monkey...
  13. doi request reprint Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering
    Thomas H Pillow
    Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, United States
    J Med Chem 57:7890-9. 2014
    ....
  14. doi request reprint A multiplexed hybrid LC-MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study
    Keyang Xu
    Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 6:1781-94. 2014
    ..However, these studies present bioanalytical challenges for ligand-binding assays (LBAs). Recent MS-based protein quantification offers an alternative for bioanalysis...
  15. pmc A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer
    Brendan Bender
    Department of Clinical Pharmacology, Genentech Inc, South San Francisco, California, USA
    AAPS J 16:994-1008. 2014
    ..The two modeling approaches provide flexibility based on available analytical measurements for T-DM1 and a framework for designing ADC studies and PK-pharmacodynamic modeling of ADC efficacy- and toxicity-related endpoints...